Heterogeneous clinical spectrum of anti-SRP myositis and importance of the methods of detection of anti-SRP autoantibodies: a multicentric study
- 802 Downloads
Anti-signal recognition particle (SRP) antibodies are important serological markers for the diagnosis and the prognosis of idiopathic inflammatory myopathy (IIM), especially to distinguish immune-mediated necrotizing myopathy (IMNM). This study was set up to investigate the phenotype associated with anti-SRP antibodies and to evaluate the methods for detecting these antibodies. Clinical and biological data were retrospectively obtained from 60 adult patients with anti-SRP antibodies detected by a dot immunoassay from 12 centers. Thirty-six (60 %) out of these 60 patients suffered from an IIM, and among them, 21 patients were diagnosed as IMNM. Among patients with a definite IIM, proximal weakness and myalgia were prominent symptoms at the time of diagnosis. Only few patients displayed severe extra-muscular symptoms such as cardiac involvement or severe myositis. Mean creatine kinase levels were high for all patients except for two of them. When testing by indirect immunofluorescence (IIF) on HEp2 cells, the fraction of patients displaying the typical anti-SRP fine speckled staining of the cytoplasm was higher in patients with IIM (30/36) (83 %) than in patients with non-IIM (3/24) (12.5 %) (p < 0.0001). Thirty (91 %) out of 33 patients with a positive immunodot and a characteristic IIF cytoplasmic staining suffered from a clinical definite myositis, whereas only 6 (22 %) out of 27 patients with a positive immunodot but a negative cytoplasmic pattern suffered from a myositis (p < 0.00001). This series highlights the strong heterogeneity of anti-SRP positivity that encompassed IMNM and non-IMNM and supports the necessity of considering both IIF and dot immunoassay to confirm the diagnosis of anti-SRP-associated myositis.
KeywordsAnti-SRP antibodies Immune-mediated necrotizing myopathy Immunodot Indirect immunofluorescence
We gratefully acknowledge the patients and the contributions made by the clinicians of all hospitals for the clinical data and especially: Pr JF Cordier JF, Pr. V. Cottin, Dr C. Khouatra, Dr J. Traclet, Pr J. Tebib, Pr J. Ninet, Dr G. Devouassoux, Dr B. Coppéré, Dr H. Gervais-Bernard, Dr E. Monard; Hospices Civils de Lyon; Dr C. Doche, CHG Chambéry, France; Pr J. Authier, neurology department, hôpital Henri Mondor, APHP, Créteil, France; Dr Steven Vanderschueren Catholic University of Leuven, University Hospitals Leuven; Belgique. We acknowledge Immunobiotec, CRB, HCL Lyon BB003300046.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands. Neuromuscul Disord. 2004;14:337–45.CrossRefPubMedGoogle Scholar
- 18.Hengstman GJ, Brouwer R, Egberts WT, Seelig HP, Jongen PJ, van Venrooij WJ, et al. Clinical and serological characteristics of 125 Dutch myositis patients. Myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies. J Neurol. 2002;249:69–75.CrossRefPubMedGoogle Scholar